Literature DB >> 18021926

Reversible splenial lesion in influenza virus encephalopathy.

Kousaku Matsubara1, Misaki Kodera, Hiroyuki Nigami, Kazuo Yura, Takashi Fukaya.   

Abstract

We describe a rare case of clinically mild, influenza-associated encephalopathy with a reversible splenial lesion. A 12-year-old Japanese girl presented with fever and headache, followed by muscle weakness and somnolence. Magnetic resonance imaging on day 4 of her illness showed a solitary lesion of the splenium of the corpus callosum that was most prominently visualized on diffusion-weighted images. The patient was diagnosed with influenza B-associated encephalopathy. Her neurologic signs had completely recovered by day 6, and the splenial abnormalities disappeared on day 11. A review of the literature identified four additional pediatric cases of this type of influenza-associated encephalopathy: three and one were caused by influenza A and B viruses, respectively. Common features include prompt and complete recovery from clinical and radiologic abnormalities, a relatively older age (> or = 5 years), and a higher incidence among the Japanese. To better understand the pathophysiology of this encephalopathy, we examined interleukin-6, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptor 1 levels in serum and cerebrospinal fluid from this patient. The results did not reveal any elevations of these cytokines in the sera or cerebrospinal fluid, suggesting that this condition is not mediated by augmented cytokine responses.

Entities:  

Mesh:

Year:  2007        PMID: 18021926     DOI: 10.1016/j.pediatrneurol.2007.08.008

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  8 in total

1.  Transient isolated lesion of the splenium associated with clinically mild influenza encephalitis.

Authors:  Srinivas Ganapathy; Elizabeth H Ey; Barbara J Wolfson; Nadir Khan
Journal:  Pediatr Radiol       Date:  2008-07-31

2.  A case report: reversible genu lesion of the corpus callosum mimicking MERS.

Authors:  Özgün Yağmur; Geysu Karlıkaya; Simay Kara
Journal:  Neurol Sci       Date:  2017-10-02       Impact factor: 3.307

3.  TNF-alpha-dependent regulation of CXCR3 expression modulates neuronal survival during West Nile virus encephalitis.

Authors:  Bo Zhang; Jigisha Patel; Michelle Croyle; Michael S Diamond; Robyn S Klein
Journal:  J Neuroimmunol       Date:  2010-06-25       Impact factor: 3.478

4.  [Transient splenial lesion in influenza A H1N1 2009 infection].

Authors:  K Linden; O Moser; A Simon; A-M Eis-Hübinger; G Fleischhack; M Born; H Tschampa; T Rosenbaum; B Köster; M Lentze
Journal:  Radiologe       Date:  2011-03       Impact factor: 0.635

5.  Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts.

Authors:  Olaoluwa Okusaga; Robert H Yolken; Patricia Langenberg; Manana Lapidus; Timothy A Arling; Faith B Dickerson; Debra A Scrandis; Emily Severance; Johanna A Cabassa; Theodora Balis; Teodor T Postolache
Journal:  J Affect Disord       Date:  2010-10-27       Impact factor: 4.839

6.  Mild Encephalopathy with Reversible Lesions in the Splenium of Corpus Callosum and Bilateral Cerebral Deep White Matter in Identical Twins.

Authors:  Junko Tahara; Jun Shinozuka; Hitoshi Awaguni; Shin-Ichiro Tanaka; Shigeru Makino; Rikken Maruyama; Shinsaku Imashuku
Journal:  Pediatr Rep       Date:  2016-09-19

Review 7.  H1N1 encephalitis with malignant edema and review of neurologic complications from influenza.

Authors:  Paul Taylor Akins; John Belko; Timothy M Uyeki; Yekaterina Axelrod; Kenneth K Lee; James Silverthorn
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

8.  Reversible splenial lesion syndrome associated with lobar pneumonia: Case report and review of literature.

Authors:  Chunrong Li; Xiujuan Wu; Hehe Qi; Yanwei Cheng; Bing Zhang; Hongwei Zhou; Xiaohong Lv; Kangding Liu; Hong-Liang Zhang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.